Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.…
Apyx Medical Corp (APYX) (Q3 2026) Earnings Call Highlights: Surgical Aesthetics Surge Drives ...
Apyx Medical (NASDAQ: APYX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 205 employees.
The shares were at 2.400 USD on 20 November 2026, down 38.0% over 52 weeks. Its 52-week range is 2.250 USD to 5.080 USD: the price is 52.8% below the high and 6.7% above the low.
Its market capitalisation is 101.10M USD.
Apyx Medical reports return on equity of -77.1%, an operating margin of -5.5% and revenue up 9.0% year over year.
Its debt exceeds its cash by 13.97M USD, a debt-to-equity ratio of 2.71. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 6.500 USD is 170.8% above the current price. The next earnings report is expected on 11 March 2027.